Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.43 |
| ▸ | JAK3 | P52333 | 15/20 | 0.43 |
| ▸ | JAK2 | O60674 | 15/20 | 0.43 |
| ▸ | TYK2 | P29597 | 14/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2281847 | 0.90 | JAK1 (0.41) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2276856 | 0.88 | JAK1 (0.41) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2275269 | 0.87 | JAK1 (0.41) | JAK1JAK3JAK2TYK2HTR6 | |
| SCHEMBL2228322 | 0.87 | JAK1 (0.52) | JAK1JAK3JAK2TYK2HTR6 | |
| SCHEMBL2269353 | 0.87 | JAK3 (0.58) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL20289965 | 0.87 | JAK3 (0.58) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL29602542 | 0.87 | JAK3 (0.58) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2279223 | 0.86 | JAK1 (0.42) | JAK1JAK3JAK2TYK2HTR6 | |
| SCHEMBL2269216 | 0.86 | JAK1 (0.47) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL2281920 | 0.85 | JAK1 (0.40) | JAK1JAK3JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |